DFCI 11-237: A Feasibility trial of Everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic Leukemia (ALL)

  • Hijiya, Nobuko (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date11/1/13 → 8/31/50

Funding

  • Dana Farber Cancer Institute
  • Novartis Pharmaceuticals Corporation